Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received a consensus rating of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.45.

Several equities research analysts have recently issued reports on HCAT shares. Stifel Nicolaus decreased their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, February 27th. Canaccord Genuity Group decreased their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Citigroup decreased their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Royal Bank of Canada decreased their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Finally, Piper Sandler decreased their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th.

Health Catalyst Trading Down 1.7 %

Shares of Health Catalyst stock opened at $4.52 on Wednesday. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The firm has a market cap of $275.03 million, a PE ratio of -3.35 and a beta of 1.34. The stock has a fifty day moving average price of $5.89 and a 200-day moving average price of $7.21. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of Health Catalyst stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the transaction, the insider now owns 98,702 shares of the company’s stock, valued at $777,771.76. The trade was a 6.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Benjamin Landry sold 19,268 shares of Health Catalyst stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now directly owns 72,250 shares of the company’s stock, valued at $601,120. The trade was a 21.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 80,110 shares of company stock valued at $596,993 in the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Health Catalyst

A number of large investors have recently modified their holdings of HCAT. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock valued at $37,055,000 after acquiring an additional 944,631 shares during the last quarter. Alyeska Investment Group L.P. boosted its position in shares of Health Catalyst by 74.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock valued at $14,277,000 after acquiring an additional 861,150 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $6,858,000. Portolan Capital Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $5,402,000. Finally, Kennedy Capital Management LLC boosted its position in shares of Health Catalyst by 42.7% during the 4th quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock valued at $13,369,000 after acquiring an additional 565,445 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.